{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-082546","form_type":"8-K","ticker":"PASG","cik":"0001787297","company_name":"Passage BIO, Inc.","filed_at":"2023-07-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.240085+00:00","generated_at":"2026-06-13T05:43:01.759746+00:00","sec_items":["5.02","8.01"],"event_type":"leadership","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Passage Bio announces CFO/CTO departures, 26% workforce reduction, extends cash runway into Q4 2025","bullets":["CFO Simona King and CTO Alex Fotopoulos to depart July 28, 2023; Fotopoulos may consult through July 2024.","Kathleen Borthwick appointed Interim CFO; base salary $382k, monthly stipend $2k, 35% bonus target, 20k stock options.","Workforce reduced by ~26% primarily in CMC group to cut operating expenses.","Cash, equivalents, and marketable securities now expected to fund operations into Q4 2025, beyond multiple clinical milestones."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-082546","json":"https://secwatch.observer/filing/0001104659-23-082546.json","markdown":"https://secwatch.observer/filing/0001104659-23-082546.md","text":"https://secwatch.observer/filing/0001104659-23-082546.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787297/000110465923082546/0001104659-23-082546-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787297/000110465923082546/tm2321606d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T05:43:01.759746+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1aae6c636f","claim":"Simona King departed as Chief Financial Officer at Passage BIO, Inc..","evidence_excerpt":"Simona King, the Company’s Chief Financial Officer, and Alex Fotopoulos, the Company’s Chief Technical Officer, will separate from the Company, effective on or about July 28, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787297/000110465923082546/0001104659-23-082546-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"separated"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"c943fc20e2","claim":"Alex Fotopoulos departed as Chief Technical Officer at Passage BIO, Inc..","evidence_excerpt":"Simona King, the Company’s Chief Financial Officer, and Alex Fotopoulos, the Company’s Chief Technical Officer, will separate from the Company, effective on or about July 28, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787297/000110465923082546/0001104659-23-082546-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"separated"},{"label":"Role","value":"Chief Technical Officer"}],"fact_type":"executive_change"},{"claim_id":"f6d1055452","claim":"Kathleen Borthwick was appointed as Senior Vice President and Interim Chief Financial Officer at Passage BIO, Inc..","evidence_excerpt":"On July 15, 2023, Kathleen Borthwick, the current Vice President, Finance of the Company was appointed to serve as Senior Vice President and Interim Chief Financial Officer, effective on or about July 28, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787297/000110465923082546/0001104659-23-082546-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Senior Vice President and Interim Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}